BR112014016648A8 - derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos - Google Patents

derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos

Info

Publication number
BR112014016648A8
BR112014016648A8 BR112014016648A BR112014016648A BR112014016648A8 BR 112014016648 A8 BR112014016648 A8 BR 112014016648A8 BR 112014016648 A BR112014016648 A BR 112014016648A BR 112014016648 A BR112014016648 A BR 112014016648A BR 112014016648 A8 BR112014016648 A8 BR 112014016648A8
Authority
BR
Brazil
Prior art keywords
preparation process
pharmaceutical use
derivatives
polycyclic derivatives
polycyclic
Prior art date
Application number
BR112014016648A
Other languages
English (en)
Other versions
BR112014016648B1 (pt
BR112014016648A2 (pt
Inventor
Wang Chunfei
Yang Fanglong
Han Jihui
Zhang Ling
Dong Qing
Wang Yang
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of BR112014016648A2 publication Critical patent/BR112014016648A2/pt
Publication of BR112014016648A8 publication Critical patent/BR112014016648A8/pt
Publication of BR112014016648B1 publication Critical patent/BR112014016648B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos". a presente invenção refere-se a derivados policíclicos representados pela fórmula geral (i), métodos de preparação dos mesmos, composições farmacêuticas contendo esses derivados e usos dos mesmos como agentes terapêuticos, especialmente como agonista de gpr40 e na preparação de fármacos para tratar doenças como diabetes e distúrbios metabólicos, etc., em que cada substituinte na fórmula geral (i) tem a mesma definição da fornecida na descrição.
BR112014016648-0A 2012-01-12 2012-12-27 derivados policíclicos, seus usos e seu processo de preparação, e composição farmacêutica BR112014016648B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210008286 2012-01-12
CN201210008286.9 2012-01-12
PCT/CN2012/087606 WO2013104257A1 (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
BR112014016648A2 BR112014016648A2 (pt) 2017-06-13
BR112014016648A8 true BR112014016648A8 (pt) 2017-07-04
BR112014016648B1 BR112014016648B1 (pt) 2020-10-27

Family

ID=48781054

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016648-0A BR112014016648B1 (pt) 2012-01-12 2012-12-27 derivados policíclicos, seus usos e seu processo de preparação, e composição farmacêutica

Country Status (15)

Country Link
US (1) US9139548B2 (pt)
EP (1) EP2803664B1 (pt)
JP (1) JP6122871B2 (pt)
KR (1) KR102036547B1 (pt)
CN (1) CN103429581B (pt)
AU (1) AU2012365706B2 (pt)
BR (1) BR112014016648B1 (pt)
CA (1) CA2860353A1 (pt)
HK (1) HK1188781A1 (pt)
MX (1) MX357780B (pt)
RU (1) RU2621039C1 (pt)
TW (1) TWI588136B (pt)
UA (1) UA115975C2 (pt)
WO (1) WO2013104257A1 (pt)
ZA (1) ZA201404625B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015062486A1 (en) * 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104788412B (zh) * 2014-01-22 2017-02-15 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
EP3177285B1 (en) 2014-08-08 2020-09-23 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3206756B1 (de) 2014-10-14 2018-09-19 Basf Se Verwendung von hexadeca-8,15-dienal als aromachemikalie
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
CN108236609B (zh) * 2016-12-27 2022-10-21 江苏恒瑞医药股份有限公司 一种gpr40激动剂药物组合物及其制备方法
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700557A (es) * 1994-07-22 1997-12-31 Byk Gulden Lomberg Chem Fab Dihidrobenzofuranos.
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1660428A1 (en) 2003-08-20 2006-05-31 Eli Lilly And Company Ppar modulators
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US7456218B2 (en) * 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
MX2008011615A (es) * 2006-03-14 2008-09-22 Amgen Inc Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
EP2431367A3 (en) * 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
CA2740366A1 (en) 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8492582B2 (en) 2009-01-30 2013-07-23 Toyama Chemical Co., Ltd. N-acyl anthranilic acid derivative or salt thereof
JPWO2010123016A1 (ja) * 2009-04-22 2012-10-25 アステラス製薬株式会社 カルボン酸化合物
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
US8299117B2 (en) * 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof

Also Published As

Publication number Publication date
HK1188781A1 (zh) 2014-05-16
EP2803664B1 (en) 2018-11-21
MX357780B (es) 2018-07-24
JP6122871B2 (ja) 2017-04-26
WO2013104257A1 (zh) 2013-07-18
ZA201404625B (en) 2015-11-25
BR112014016648B1 (pt) 2020-10-27
JP2015503595A (ja) 2015-02-02
EP2803664A4 (en) 2015-10-28
KR20140117498A (ko) 2014-10-07
UA115975C2 (uk) 2018-01-25
CA2860353A1 (en) 2013-07-18
EP2803664A1 (en) 2014-11-19
AU2012365706B2 (en) 2015-08-20
AU2012365706A1 (en) 2014-07-24
MX2014008125A (es) 2014-09-22
TW201329058A (zh) 2013-07-16
BR112014016648A2 (pt) 2017-06-13
CN103429581A (zh) 2013-12-04
RU2621039C1 (ru) 2017-05-31
US20150005282A1 (en) 2015-01-01
TWI588136B (zh) 2017-06-21
CN103429581B (zh) 2015-08-26
US9139548B2 (en) 2015-09-22
KR102036547B1 (ko) 2019-10-25

Similar Documents

Publication Publication Date Title
BR112014016648A2 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112015016358A2 (pt) composições nutritivas contendo um componente neurológico e usos das mesmas
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112015028212A2 (pt) derivado de fenol e método de preparação e utilização dos mesmos na medicina
BR112015007647A2 (pt) derivados de quetamina
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112014014877A2 (pt) derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos
BR112014004732A2 (pt) composto benzotiazolona
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2650 DE 19-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.